Vaccine Adjuvants Market

The global vaccine adjuvants market is anticipated to reach USD 0.96 billion by 2029 from USD 0.70 billion in 2024, with a significant CAGR of 6.5%. The growing demand for the increasing prevalence of infectious diseases and the development of next-generation adjuvants, such as saponin-based adjuvants and TLR agonists, are some of the factors projecting market growth. Furthermore, rise in demand for personalized and combination vaccines, increasing awareness about zoonotic diseases and demand for vaccines is futher rising demand for vaccine adjuvants subsequently propelling the market growth.

The market for vaccine adjuvants market is competitive, with key players strategizing to capture the majority market share. Prominent players in the vaccine adjuvants market are GSK Plc (UK), SEPPIC (France), Croda International Plc (UK), SPI Pharma (UK), Agenus Inc. (US), Phibro Animal Health Corporation (US), Aurorium (US), Dynavax Technologies Corporation (US), Novavax (US), and Merck KGaA (Germany), among others. The market players have adopted various strategies such as development of advanced products, partnerships, contracts, expansions, and acquisitions to strengthen their position in the vaccine adjuvants market.

To know about the assumptions considered for the study download the pdf brochure

GSK Plc is one of the prominent players in vaccine adjuvants market. The company boasts strong research and development capabilities, a comprehensive adjuvant portfolio, and a strategic focus on innovative formulations. As a global leader in the vaccine adjuvants market, GSK leverages its extensive presence across North America, Europe, Asia, and emerging markets. This broad geographical reach enables GSK to address diverse healthcare needs and capitalize on regional growth opportunities in vaccine development and delivery.

SEPPIC, a leading player in the vaccine adjuvants market, is renowned for its innovative and versatile adjuvant solutions. Its key strengths include a diverse product portfolio featuring squalene-based emulsions, polymer-based adjuvants, and other advanced formulations tailored for both human and veterinary vaccines. The company has a robust geographic presence, with strong operations in Europe, North America, and emerging markets, allowing it to support global vaccine development initiatives. The company prioritizes R&D investments to develop next-generation adjuvants that improve immunogenicity and address unmet needs in human and veterinary vaccines. Its focus on the launch of new products further strengthens the market position. In October 2022, the company launched MONTANIDE GR 01, which is used to formulate veterinary oral vaccines by emulsification with aqueous antigens.

Croda  International Plc. is a global leader in vaccine adjuvants, leveraging its extensive geographic presence and strong R&D capabilities. With operations spanning North America, Europe, and emerging markets in Asia Pacific and Latin America. The company offers a diverse portfolio of high-quality adjuvants, including novel technologies tailored to enhance vaccine efficacy and stability. Its advanced manufacturing facilities adhere to stringent regulatory standards, ensuring consistent supply. Croda’s strategic choices in the vaccine adjuvants market reflect its commitment to innovation, sustainability, and global expansion.

Related Reports:

Vaccine Adjuvants Market by Product (Emulsions, Pathogen, Saponin, Particulate), ROA (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Vaccine (Human, Veterinary (Companion, Livestock)), Type (Organic, Inorganic) - Global Forecast to 2029

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]